AbbVie Inc. Files 8-K on Financial Operations
Ticker: ABBV · Form: 8-K · Filed: Jul 25, 2024 · CIK: 1551152
| Field | Detail |
|---|---|
| Company | Abbvie Inc. (ABBV) |
| Form Type | 8-K |
| Filed Date | Jul 25, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, debt, disclosure
Related Tickers: ABBV
TL;DR
AbbVie dropped an 8-K on 7/25 detailing financial ops and senior notes.
AI Summary
On July 25, 2024, AbbVie Inc. filed an 8-K report detailing its financial condition and results of operations. The filing includes information on various senior notes, such as the 0.750% Senior Notes due 2027 and 2.125% Senior Notes due 2028, indicating ongoing financial activities and debt management.
Why It Matters
This filing provides insight into AbbVie's current financial standing and debt structure, which is crucial for investors assessing the company's stability and future prospects.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of financial information and does not indicate any immediate or significant risks.
Key Players & Entities
- AbbVie Inc. (company) — Registrant
- 0.750% Senior Notes due 2027 (dollar_amount) — Debt Instrument
- 2.125% Senior Notes due 2028 (dollar_amount) — Debt Instrument
- July 25, 2024 (date) — Report Date
FAQ
What is the primary purpose of this 8-K filing by AbbVie Inc.?
The primary purpose of this 8-K filing is to report on AbbVie Inc.'s Results of Operations and Financial Condition, as well as to file Financial Statements and Exhibits.
What specific debt instruments are mentioned in the filing?
The filing mentions several senior notes, including the 0.750% Senior Notes due 2027, 2.125% Senior Notes due 2028, 2.625% Senior Notes Due 2028, 2.125% Senior Notes Due 2029, and 1.250% Senior Notes due 2031.
On what date was this 8-K report filed?
This 8-K report was filed on July 25, 2024.
What is AbbVie Inc.'s Standard Industrial Classification (SIC) code?
AbbVie Inc.'s Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Where is AbbVie Inc. incorporated and what is its fiscal year end?
AbbVie Inc. is incorporated in Delaware (DE) and its fiscal year ends on December 31 (1231).
Filing Stats: 482 words · 2 min read · ~2 pages · Grade level 9.4 · Accepted 2024-07-25 07:41:17
Key Financial Figures
- $0.01 — ange on which registered Common Stock, $0.01 Par Value ABBV New York Stock Exchange
Filing Documents
- abbv-20240725.htm (8-K) — 39KB
- abbv-20240630xexhibit991.htm (EX-99.1) — 454KB
- abbvieimage1a53.jpg (GRAPHIC) — 15KB
- 0001551152-24-000026.txt ( ) — 748KB
- abbv-20240725.xsd (EX-101.SCH) — 4KB
- abbv-20240725_def.xml (EX-101.DEF) — 19KB
- abbv-20240725_lab.xml (EX-101.LAB) — 35KB
- abbv-20240725_pre.xml (EX-101.PRE) — 20KB
- abbv-20240725_htm.xml (XML) — 8KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition On July 25, 2024, AbbVie Inc. issued a press release announcing financial results for the second quarter ended June 30, 2024. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Exhibit 99.1 Press Release dated July 25 , 2024 (furnished pursuant to Item 2.02). 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABBVIE INC. Date: July 25, 2024 By: /s/ Scott T. Reents Scott T. Reents Executive Vice President, Chief Financial Officer